N-Acetyl Selank vs Noopept
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
N-Acetyl Selank
Acetylated variant of Selank with enhanced stability and bioavailability. The N-acetyl modification protects the peptide from rapid enzymatic degradation, extending its active half-life relative to standard Selank. Provides anxiolytic, nootropic, and immunomodulatory effects comparable to or exceeding standard Selank with potentially greater duration from each dose.
Full profileNoopept
Dipeptide-derived nootropic developed in Russia and used across Eastern Europe as a cognitive enhancer and neuroprotective agent. Structurally related to piracetam but estimated to be approximately 1000× more potent by weight. Rapidly crosses the blood-brain barrier and is hydrolyzed to the endogenous neuropeptide cycloprolylglycine, which is proposed as its primary active metabolite.
Full profile| N-Acetyl Selank | Noopept | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | Selank-A, N-Ac-Selank, acetylated selank, N-acetyl selank | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–500mcg mcg, 1–2x daily intranasal | 5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles) |
| Administration | Intranasal spray, Subcutaneous injection | Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal |
| Key side effects | Mild sedation (acute), Fatigue, Headache (rare), Nasal irritation (intranasal route) | Headache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: N-Acetyl Selank — Intranasal spray, Subcutaneous injection; Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal.
- Dosing units differ: N-Acetyl Selank is dosed in mcg, Noopept in mg — they operate at different scales.
- Frequency: N-Acetyl Selank is typically 1–2x daily intranasal; Noopept is 1–3x daily oral or sublingual (8–12 week cycles).
How each works
N-Acetyl Selank
N-Acetyl Selank shares Selank's core mechanism — BDNF/NGF upregulation, enkephalinase inhibition, and GABA-A receptor complex modulation — with improved metabolic stability from the N-terminal acetyl group. The acetyl modification protects against aminopeptidase N and angiotensin-converting enzyme cleavage, extending the peptide's active residence time in neural tissue after intranasal administration.
Noopept
Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.